aTyr Pharma(US:LIFE) Globenewswireยท2025-10-14 22:40Core Viewpoint - Western Uranium & Vanadium Corp. has successfully closed a bought deal private placement financing, raising approximately Cdn$5,900,000 through the issuance of 6,555,556 units at Cdn$0.90 per unit, each unit consisting of one common share and one warrant [1][2]. Financing Details - The financing involved the issuance of units, with each unit priced at Cdn$0.90, leading to total gross proceeds of about Cdn$5,900,000 [1]. - Each warrant is exercisable for one common share at a price of Cdn$1.20 for a period of four and a half years from issuance [1]. Use of Proceeds - The net proceeds from the offering will be allocated to several key areas: - Permitting of Mustang Mineral Processing Plant - Drilling, monitoring, and permitting for the San Rafael Uranium Project - Mine development and maintenance across the production portfolio - Permitting and baseline data collection for Topaz Mine - General corporate working capital purposes, including administrative costs [2]. Regulatory and Underwriting Information - The offering was conducted under the listed issuer financing exemption (LIFE) and is not subject to any statutory hold period under Canadian securities laws [3]. - An underwriting agreement was established with A.G.P. Canada Investments ULC, which acted as the sole underwriter and bookrunner, receiving a 7% cash commission and 229,444 broker warrants [4]. Company Overview - Western Uranium & Vanadium Corp. is focused on developing high-grade uranium and vanadium production, with ongoing projects including the Mustang Mineral Processing Plant and the Sunday Mine Complex [6]. - The company is actively pursuing additional opportunities to acquire and develop properties near its processing plant site [6].